Improved Drug Susceptibility Testing (DST) for Mycobacteria

The Improved Drug Susceptibility Testing for Mycobacteria opportunity is a forecasted federal funding initiative from the National Institutes of Health, specifically administered through the National Institute of Allergy and Infectious Diseases within the U.S. Department of Health and Human Services. This program is designed to support research that aligns with NIAID’s broader mission to combat infectious diseases and improve public health outcomes. The initiative is grounded in statutory authority under the Public Health Service Act and federal regulations governing research grants, reflecting a long-standing federal commitment to advancing biomedical innovation. The primary purpose of this opportunity is to accelerate the development of improved drug susceptibility testing methods for mycobacterial infections. These include tuberculosis and non-tuberculous mycobacterial infections, both of which present growing public health challenges. Tuberculosis remains one of the leading causes of death from infectious disease globally, and the rise of drug-resistant strains has intensified the need for more effective diagnostic tools. Similarly, increasing rates of non-tuberculous mycobacterial lung disease in the United States, particularly among vulnerable populations such as older adults, underscore the urgency of improved testing methodologies. Funding under this program will support research focused on developing innovative diagnostic assays that can more rapidly and accurately determine drug susceptibility. Current testing methods rely heavily on culture-based techniques, which are time-consuming and limit timely clinical decision-making. This opportunity encourages the development of both genotypic and phenotypic approaches that reduce or eliminate the need for full culture growth. The ultimate goal is to enable faster identification of effective treatments, reduce the spread of resistant strains, and improve patient outcomes. Eligible applicants for this opportunity are broad and inclusive, encompassing a wide range of organizational types. These include institutions of higher education, nonprofit organizations with or without 501(c)(3) status, small and large businesses, and various levels of government entities including state, county, city, and tribal governments. Additional eligible entities include federal agencies, U.S. territories, faith-based organizations, and foreign institutions. This inclusive eligibility framework reflects the collaborative and interdisciplinary nature of the research required to address complex infectious disease challenges. The application process is expected to follow standard NIH submission procedures, likely requiring submission through Grants.gov. While specific application components are not detailed in the forecast, NIH cooperative agreement mechanisms typically involve detailed research plans, budget justifications, and institutional documentation. There is no indication of a required pre-application such as a letter of intent at this stage. Applicants should prepare for a competitive review process based on scientific merit, innovation, feasibility, and alignment with program goals. The timeline for this opportunity indicates that it is currently in a forecast stage, with an estimated application posting date in March 2027 and a projected application deadline in May 2027. Awards are anticipated to be made in June 2028, with project start dates aligned to that same period. The program is not explicitly described as recurring, and therefore should be treated as a single-cycle opportunity unless further updates indicate otherwise. For inquiries, applicants are directed to contact the NIAID Division of Microbiology and Infectious Diseases via the provided program email address. No individual contact person is specified. As a forecasted opportunity, additional details including full application requirements and evaluation criteria are expected to be released in the official funding announcement closer to the posting date.